<PAGE>2
FORM 10-KSB
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
[X] 15,ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended: 3/31/00
OR
[ ]15,TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number - 000-28787
Micro Laboratories, Inc.
Exact name of Registrant as specified in its charter)
NEVADA 05-049-4587
(State or other (Primary Standard Industrial (I.R.S. Employer
jurisdictions Classification Code Number) Identification number)
of incorporation
or organization
29 Lakeside Drive, Johnston, Rhode Island 02919
(Address of principal executive offices) (Zip Code)
Telephone: (401) 949-3562
(Registrant's telephone number, including area code)
Securities registered pursuant to
Section 12(b) of the Act: None
Securities registered pursuant to
Section 12(g) of the Act: Common Stock, $.001 par value
Check whether the Company (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act during the
preceding 12 months (or such shorter period that the Company was
required to file such reports), and (2) has been subject to such
filing requirements for at least the past 90 days.
Yes __x__ No _____
Check if there is no disclosure of delinquent filers in response to
Item 405 of Regulation S-B is not contained in this form, and no
disclosure will be contained, to the best of Company's knowledge, in
definitive proxy or information statements incorporated by reference
in Part III of this Form 10-KSB or any amendment to this Form 10-KSB.
[x]
The Company's revenues for its most recent fiscal year were $0.00. As
of March 31, 2000, the market value of the Company's voting $.00l par
value common stock held by non-affiliates of the Company was $
10,737,500.
The number of shares outstanding of Company's class of common
stock, as of March 31, 2000 was 11,337,500 shares of its $.001 par
value common stock.
Check whether the Issuer has filed all documents and reports required
to be filed by Section 12, 13 or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court.
Yes ____ No _____
No documents are incorporated into the text by reference.
Transitional Small Business Disclosure Format (check one)
Yes No x
-------- --------
<PAGE>3
PART I
ITEM 1. BUSINESS - General
Business of Corporation. The operations and objectives of the
Corporation are to produce, market and distribute a line of oral
sprayvitamins, trade name "Micro SprayT". Micro intends to produce,
market and distribute an additional product line of, minerals, herbs
and other oral absorption products in the United States and the
international market. Therefore, Micro's financial viability will
depend almost exclusively on Micro's ability to generate revenues from
its operation, and the production of the above product lines. Micro
will not have the benefit of reducing its financial risks by relying
on revenues derived from other operations.
Competition. There is significant competition in the vitamin,
minerals and nutritional supplement industry. Micro will compete with
established companies and other entities (many of which possess
substantially greater resources than Micro). Almost all of the
companies with which Micro will compete are substantially larger, have
more substantial histories, backgrounds, experience and records of
successful operations, greater financial, technical, marketing and
other resources, more employees and more extensive facilities than
Micro now has, or will in the foreseeable future. It is also likely
that other competitors will emerge in the near future. There is no
assurance that Corporation will compete successfully with other
established vitamin, minerals and nutritional supplement
manufacturers. Micro shall compete on the basis of quality in addition
to a price basis. Inability to compete successfully might result in
increased costs, reduced yields and additional risks to the investors
herein
Employees. Micro has one full time and two part time employees.
Micro shall employ individuals as required.
Governmental Regulation. Micro is not subject to governmental
regulation other those regulations, which apply to manufacturing.
Micro will need to meet the requirements of the Food and Drug
Administration for food processing standards.
Seasonal Nature of Business Activities. Micro's operations shall not
be seasonal.
Products. Micro currently has six different nutritional health
products. All natural ingredients are used in each product. The price
of the products range from retail pricing of approximately $7.00 to
$40.00 and wholesale prices of $5.00 to $20.00. Micro's products are:
Adult Multiple Vitamin, Children's Multiple Vitamin, Vitamin B-12,
Adult B-Complex with C, Children's B-Complex with C, Zinc plus Vitamin
C.
The nutritional supplement industry is not regulated by the Food and
Drug Administration. The Food and Drug Administration has tried
unsuccessfully in the past to pass legislation labeling vitamins as
drugs. Due to this position, Micro does not publish any information
that could be considered as "'prescribing". The Corporation attempts
to cooperate with this agency whenever possible and seeks professional
legal counsel experienced and specializing in Food and Drug
Administration matters.
The Food and Drug Administration prohibits any companies from
providing information to the customer as to what the product is for
and why it works. The Food and Drug Administration views that if the
marketer is making any suggestions or claims as to what the product is
for then that is considered prescribing and as such the product is a
drug. If the product is determined to be a drug, then it needs to be
licensed as one and available only as a prescription item. The Food
and Drug Administration has tried unsuccessfully in the past to pass
legislation labeling vitamins as drugs. Due to this position, Micro
does not publish any information that could be considered as
"prescribing".
Micro SprayT Delivery System. Micro has developed "Micro SprayT", a
delivery system in the form of a spray that is sprayed directly onto
the mouth in the form of a fine mist. Micro SprayT enters the
delicate tissue of the mouth and is absorbed into the bloodstream and
assimilated throughout the body. Micro SprayT consists of vitamins
and nutrients in an aqueous solution that is delivered through a non-
aerosol pump.
<PAGE>4
In-house studies have determines that Micro SprayT, derived from
vegetable sources, increases the quantity of nutrients that enter into
the bloodstream, provides proper nutrient levels and increases the
rate at which a nutrient is absorbed.
Current Industry Background and Delivery Systems. The metabolism of
nutrients consist of four important steps: digestion, assimilation,
utilization and excretion. Digestion takes place in either the
stomach where the fluids are acidic, or the small intestines where the
fluids are alkaline. The proper balance of acid levels in these vital
organs is crucial to the digestion process, yet as people age,
increasingly less of these fluids are produced and as a result, the
level of nutrient absorption is decreased.
NBC's Today Show reported that when a variety of name brand vitamins
were tested, 36% of the vitamin pills failed to disintegrate quickly
enough to be absorbed into the bloodstream. In order to combat this
problem, tablet manufacturers often attach a catalyst (chelator) to
the minerals that will aid in the digestion process, however, normally
up to 80% of the tablet can become chelator and only 20% of the
content is actually pure mineral. In addition, minerals are typically
unstable and easily destroyed in the digestive tract and the acid in
the stomach can actually deactivate enzymes before they reach the site
of optimal activity. To counter this difficulty, manufacturers
enteric-coat pancreatic and other similar acid sensitive ingredients
to prevent destruction in the stomach. The coating must be resistant
to acid in the stomach, yet dissolve in the alkaline environment of
the small intestine. As individuals vary greatly in the levels of
acid in their stomachs and the alkaline levels of their small
intestines, if coatings are improperly balanced or designed in a
generic environment, the supplement will be wasted.
Assimilation takes place primarily in the small intestines where
adverse effects can result from a multitude of factors. Some nutrients
react to one another and compete for absorption. Some even require
that your body secretes special proteins as carriers before being
absorbed, while others are best absorbed when fat and oils are induced
into the body's diet as a carrier. The result of assimilation
complications is known to cause, among other ailments, unpleasant side
effects such as nausea and gastrointestinal discomfort. In addition,
digestive organs such as the liver, kidneys and stomach are taxed
unnecessarily, as the nutrients do not always break down and might not
offer the body any nutritional value.
Manufacturing. Micro will package its product line. Most packaging
will be done in house, some will be done by independent packaging
companies across the nation. Micro supplies the packaging Corporation
with the finished product in measured-premixed form, so that a
measured amount can be inserted into the vials by the packaging
Corporation. The vials are filled, labeled and packaged for
distribution. Micro will offer variations of their product for
private label.
Service and Support. Micro guarantees its products to 100%
satisfaction. If a customer is not satisfied with the product for any
reason, the product will be replaced or the price refunded.
Marketing. Micro shall position its marketing efforts to target large
retail store chains and is presently in negotiations with several
large distributors. Micro has entered into an agreement with three
large distributors and marketing representatives for the distribution
of its products in the northwest, mid west, and New England. The
distributors receive commissions on each product sold. The target
market extends to drug, grocery, health food stores, fitness clubs,
established physicians, chiropractors and even veterinarians.
New Products. Micro shall continue to pursue the development of new
products as funds allow.
Advertising and Name Brand Awareness. In order to increase the
number of new distributors and expand the customer base, Micro shall
utilize a portion of the proceeds of the Offering to finance media
campaigns encompassing a broad communication spectrum ranging from
network television to the Internet, and trades.
International Markets. Micro shall pursue its expansion into the
foreign markets.
<PAGE>5
ITEM 2. PROPERTIES.
Micro's executive offices are located at 29 Lakeside Drive, P.O. Box
19296, Johnston, Rhode Island 02919. These offices consist of 400
square feet for office, product development, product testing and is
leased at the rate of $600 per month.
ITEM 3. LEGAL PROCEEDINGS.
The Company is named as defendant in legal action alleging breach of
fiduciary duties. The Company intends to vigorously defend this
action and is not inclined to seek an out of court settlement. The
case is currently in the discovery stage and the ultimate resolution
of the matter is not ascertainable at this time.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
During the fourth quarter of the fiscal year ended March 31, 2000, no
matters were submitted to a vote of the Company's security holders,
through the solicitation of proxies.
<PAGE>6
PART II
ITEM 5. MARKET FOR COMPANY'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS
The Company's common stock is traded in the over-the-counter market
and listed on the NASDAQ Bulletin Board under the symbol "MLAR-BB.
The following table sets forth the range of high ask and low bid
quotations for the Company's common stock for each quarter since
commencement of trading (July 8, 1998), as reported by the OTC
Bulletin Board. The Company's market makers are Hill, Sharpe
Capital, Inc. and Paragon Securities. The quotations represent inter-
dealer prices without retail markup, markdown or commission, and may
not necessarily represent actual transactions.
Quarter Ended High Ask Low Bid
9/30/98 $4.00 $4.00
12/31/98 $6.062 $.375
3/31/99 $3.250 $.187
6/30/99 $3.00 $.0437
9/30/99 $.750 $.218
12/31/99 $2.125 $.218
3/31/00 $.52 $.37
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS.
Trends and Uncertainties. Demand for Micro's products will be
dependent on, among other things, general economic conditions, which
are cyclical in nature. Inasmuch as a major portion of the
Corporation's activities is the receipt of revenues from the sale of
its products, Micro's business operations may be adversely affected by
its competitors and prolonged recessionary periods.
Micro is entering a phase of conversion from a Development Stage
Corporation to an Operational Corporation. Agreements have been
reached to provide key personnel in the areas of marketing and sales.
An agreement has been reached with three large distributors to include
the west coast, mid west and New England. Preliminary market research
was conducted to arrive at the flavorings for the Micro SprayT product
line. Micro sent a representative to the National Association of
Chain Drug Stores (NACDS) trade convention in Philadelphia, PA also
the packaging show in Chicago Ill. The Corporation plans to use a
"target" marketing approach for the distribution of its Micro SprayT
product line.
Capital and Source of Liquidity. Micro currently has no material
commitments for capital expenditures.
For the year ended March 31, 2999, Micro acquired property and
equipment of $15,469 and received proceeds form the sale of equipment
of $9,825. Micro repaid loans to related parties of $261. As a
result, for the year ended March 31, 2000, Micro had net cash used for
investing activities of $5,383.
For the year ended March 31, 1999, Micro acquired intangible assets
valued at $129,238 and acquired property and equipment of $25,756.
For the year ended March 31, 1999, Micro made shareholder loans of
$24,710. Micro had a note payable of $45,000, had $5,500 due to
shareholder and $64,030 due to a related party for the year ended
March 31, 1999. As a result, Micro had net cash used in investing
activities of $65,174 for the year ended March 31, 1999.
For the year ended March 31, 2000, Micro had amounts due to related
parties of $15,800 resulting in net cash provided by financing
activities of $15,800.
For the year ended March 31, 1999, Micro received proceeds of $182,198
from the issuance of its common stock. Micro also received services
valued at $572,455 in exchange for its common stock for the year ended
March 31, 1999. As a result, Micro had net cash provided by
financing activities of $754,653 for the year ended March 31, 1999.
On a long term basis, liquidity is dependent on commencement of
operations as discussed above, receipt of revenues, additional
infusions of capital and debt financing. Micro believes that
additional capital and debt financing in the short term will allow
Micro to increase its marketing and sales efforts and become a fully
<PAGE>7
operational Corporation thereafter resulting in increased revenue and
greater liquidity in the long term. However, there can be no
assurance that Micro will be able to obtain additional equity or debt
financing in the future, if at all.
Results of Operations.
Micro is accurately classified as a "development stage Corporation"
and as such has conducted startup and development operations that
include:
completed photo shoots, created Corporation logos, brochures, sales
literature, product labels and packaging design, UPCs
prepared the product line of six items for distribution roll out
completed negotiations with three large distributors to include
west coast, mid west, and New England to represent and sell the
companies product lines to national chains
Micro has not received any material revenues since inception.
For the year ended March 31, 2000, Micro had operating expenses of
$1,144,851 and had a net loss of $1,151,823 resulting in a loss per
common share of $.11. These operating expenses consisted primarily
of advertising and public relations of $371,976, legal and
professional fees of $102,121, fulfillment expense of $68,277,
research and development of $185,458, investor services of $156,000,
laboratory supplies of $2,435, telephone of $17,663, depreciation of
$8,661, amortization of $5,050, rent of $26,265, automobile expense of
$14,235, travel expense of $3,713, website start up expense of
$108,550, office supplies o $4,695, consult of $101,248, repairs and
maintenance of $2,033, postage of $1,511, bank service charges of
$806, printing of $119, dues and subscriptions of $925, utilities
expense of $936, directors compensation of $10,000, distribution
services of $5,600 and miscellaneous expense of $574.
For the year ended March 31, 1999, Micro had operating expenses of
$444,156 and had a net loss of $440,507 resulting in a loss per common
share of $.04. These operating expenses consisted primarily of
advertising and public relations of $103,008, legal and professional
fees of $111,444, research and development of $51,022, telephone
expense of 18,959, rent of $24,200, automobile expense of $14,272,
freight expense of $62,107 and other miscellaneous expenses of $59,133
Plan of Operation. Micro is in the development stage and has not
conducted any significant operations to date or received any material
operating revenues. Micro may experience problems; delays, expenses
and difficulties sometimes encountered by an enterprise in Micro's
stage of development, many of which are beyond Micro's control. These
include, but are not limited to, unanticipated problems relating to
additional costs and expenses that may exceed current estimates and
competition.
Micro is not delinquent in any of its obligations even though Micro
has generated limited operating revenues. The Corporation intends to
market its products and services utilizing cash made available from
the private sale of its securities and operations. Micro's management
is of the opinion that the proceeds of the sales of its securities and
future revenues will be sufficient to pay its expenses for the next
twelve months.
<PAGE>8
ITEM 7. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Financial Statements
[Letterhead of Cayer Prescott Clune Chatellier]
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
To the Stockholders and Board of Directors
Micro Laboratories, Inc.
We have audited the balance sheet of MICRO LABORATORIES, INC. (a
development stage Company) as of March 31, 2000 and the related
statements of operations, stockholders' equity and cash flows for the
year then ended and the period form August 8, 1997 (inception) to
March 31, 2000. The financial statements are the responsibility of
the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the
audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of MICRO
LABORATORIES, INC. for the year ended March 31, 2000 and for the
period from August 8, 1997 to March 31, 2000, and the results of its
operations and its cash flows for the period then ended in conformity
with generally accepted accounting principles.
The accompanying financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note 1
to the financial statements, the Company is a development stage
enterprise. The Company has not yet commenced its principal
operations and has focused its efforts on the raising of capital and
the development and marketing of its products. Accordingly, the
Company has no operating history, which raises substantial doubt about
its ability to continue as a going concern as discussed in Note 6.
The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
July 7, 2000
/s/Cayer Prescott Clune & Chatellier, LLP
<PAGE>9
MICRO LABORATORIES, INC.
(A Development Stage Company)
Balance Sheet
March 31, 2000
<TABLE>
ASSETS
<CAPTION>
2000
<S> <C>
Current Assets
Prepaid expenses $ 20,033
Due from related parties 27,664
Inventory 27,040
------------
Total Current Assets 74,737
------------
Property and Equipment
Machinery and equipment 47,070
Computer software 11,723
Furniture and fixtures 3,664
Leasehold improvements 2,357
------------
64,814
Less accumulated depreciation ( 16,232)
------------ -
Net Property and Equipment 48,582
Other Assets
Deposits 600
Formulas and trademarks (net of accum.amort.) 60,600
------------
Total Other Assets 61,200
-------------
Total Assets $184,519
============
LIABILITIES & EQUITY
Current Liabilities
Accounts payable $ 261,562
Due to related parites 124,830
------------
Total Current Liabilities 386,392
------------
Stockholders Equity
Common stock 11.338
Additional paid-in capital 1,531,345
Accumulated deficit (1,744,556)
-----------
Total Stockholders Equity (201,873)
-----------
Total Liabilities & Equity $184,519
===========
</TABLE>
SEE NOTES TO FINANCIAL STATEMENTS
<PAGE>10
MICRO LABORATORIES, INC.
(A Development Stage Company)
STATEMENTS OF OPERATIONS
YEAR ENDED MARCH 31, 200
AND THE PERIOD FROM AUGUST 8, 1997 (DATE OF INCEPTION)
TO MARCH 31, 2000
<TABLE>
<CAPTION>
Year Ended August 8, 1997 (inception)
March 31, 2000 to March 31, 2000
-------- ---------
<S> <C> <C>
Net Sales $ 0 $ 0
------------- -------------
Cost of goods sold 0 0
------------- -------------
Operating Expenses:
Advertising and public relations 317,976 469,406
Legal and professional fees 102,121 271,692
Fulfillment expense 68,277 68,277
Research and development 185,458 236,480
Investor services 156,000 156,000
Laboratory supplies 2,435 16,831
Payroll and payroll taxes 0 18,959
Telephone 17,663 37,264
Incorporation fees 0 6,501
Depreciation 8,662 19,280
Amortization 5,050 15,150
Rent 26,265 52,865
Automobile expense 14,235 29,705
Travel expense 3,713 9,756
Insurance expense 0 4,368
Website start up expense 108,550 116,177
Samples 0 827
Office supplies 4,695 11,795
Consulting 101,248 163,855
Freight 0 2,277
Repairs and maintenance 2,033 4,773
Meals and entertainment 0 1,312
Outside services 0 168
Postage 1,511 2,774
Bank service charges 806 1,248
Printing 119 1,635
Dues and subscriptions 925 2,227
Licenses and fees 0 2,080
Contributions 0 30
Utilities expense 936 1,534
Directors compensation 10,000 10,000
Distribution services 5,600 5,600
Miscellaneous expense 574 1,711
--------- ----------
Total Operating Expenses 1,144,851 1,742,557
--------- ----------
Loss from Operations (1,144,851) (1,742,557)
Other Income (Loss):
Loss on sale of assets (8,653) (8,653)
Interest income 1,681 6,654
--------- ---------
Net Other Income(loss) (6,972) (1,999)
--------- ---------
Net Loss $(1,151,823) $(1,744,556)
========= =========
Loss per common share and loss per common
share - assuming dilution $ 0.11 $ 0.16
=========== ===========
</TABLE>
SEE NOTES TO FINANCIAL STATEMENTS
<PAGE>11
MICRO LABORATORIES, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
YEAR ENDED MARCH 31, 2000
AND THE PERIOD FROM AUGUST 8, 1997 (DATE OF INCEPTION)
TO MARCH 31, 2000
<TABLE>
<CAPTION>
Year Ended August 8, 1997 (inception)
March 31, 2000 to March 31, 2000
-------- -----------------
<S> <C> <C>
Cash flows from operating activities:
Net income $ (1,151,823) $(1,744,556)
Adjustments to reconcile net income to
net cash used for operating activities:
Value of services received in exchange
For common stock 372,030 945,335
Depreciation and amortization 13,711 31,382
Loss on sale of equipment 8,653 8,653
(Increase) decrease:
Prepaid expenses 134,683 (20,033)
Inventory (14,886) (27,040)
Deposits 4,000 ( 600)
Increase (decrease) in:
Accounts payable 210,316 261,562
------------- -----------
Net cash used by operating activities (423,316) (545,297)
Cash Flows from Investing activities:
Acquisition of property and equipment ( 15,469) (79,142)
Acquisition of formulas and trademarks 0 (75,750)
Proceeds from sale of equipment 9,825 9,825
Repayment from (loans to) to related parties 261 (27,664)
------------ -----------
Net cash used for investing activities (5,383) (172,731)
Cash Flows from Financing activities:
Proceeds from issuance of common stock 0 593,198
Amounts due to related parties 15,800 124,830
------------ ----------
Net cash provided by financing activities 15,800 0
------------ ----------
Net decrease in cash
Cash balance, beginning of period (412,899) 0
------------ ----------
Cash balance, end of period $ 0 0
=========== ==========
</TABLE>
SEE NOTES TO FINANCIAL STATEMENTS
<PAGE>12
MICRO LABORATORIES, INC.
-------------------------
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
YEAR ENDED MARCH 31, 2000
AND THE PERIOD FROM AUGUST 8, 1997 (DATE OF INCEPTION)
TO MARCH 31, 2000
<TABLE>
<CAPTION>
Additional
Common Stock Paid In Accumulated
Shares Amount Capital Deficit
------ ------ ---------- ------------
<S> <C> <C> <C> <C>
Common stock issued for equipment through
March 31, 1998 3,100,000 $3,100 $ 1,050
Common stock issued for services rendered
Through March 31, 1998 850,000 850
Common stock issued for cash through
March 31, 1998 348,000 348 410,652
Net loss through March 31, 1998 $(152,226)
--------- -------- --------- ----------
Balance at March 31, 1998 4,298,000 4,298 411,702 (152,226)
Common stock issued for services rendered
For the year ended March 31, 1999 1,254,500 1,255 571,200
Common stock issued for cash for the year
Ended March 31, 1999 4,800,000 4,800 177,398
Net loss year ended March 31, 1999 (440,507)
--------- ------- -------- ---------
Balance at March 31, 1999 10,352,500 10,353 1,160,300 (592,733)
Common stock issued for services rendered
For the year ended March 31, 2000 985,000 985 371,045
Net loss year ended March 31, 2000 (1,151,823)
----------
Balance at March 31, 2000 11,337,500 $11,338 $1,531,345 $(1,744,556)
========== ======= ========== ===========
</TABLE>
SEE INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS' AUDIT REPORT
<PAGE>13
MICRO LABORATORIES, INC.
========================
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 2000
------------------------------------------------------------
1. SIGNIFICANT ACCOUNTING POLICIES
Background
Micro Laboratories, Inc. ("the Company") was
incorporated as a Nevada Corporation on August 8, 1997. Micro
Laboratories, Inc. is a development stage enterprise which has
undertaken the development and marketing of a line of oral spray
vitamins, nutrients, herbs and other oral absorption products as well
as gel capsules, etc. in the United States and international market.
The financial statements and notes are representations of the
Company's management, who is responsible for their integrity and
objectivity. The accounting policies of the Company are in
accordance with generally accepted accounting principles and conform
to the standards applicable to development stage companies. The
preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates
and assumptions that affect certain reported amounts and disclosures.
Accordingly, actual results could differ from those estimates.
Development Stage Enterprise
The Company is a Development Stage Company as defined in financial
accounting standards. Board Statement No. 7. As of the balance
sheet date, the Company had not yet begun principal operations. The
primary activities during the fiscal period covered by these financial
statements were raising capital and developing vitamin products (the
major source of projected revenue).
Inventories
Inventories consist of chemicals and product packaging. Inventories
are stated at the lower of cost, determined on the first-in, first-out
(FIFO) method, or market.
Cash or cash Equivalents
The Company considers all highly liquid investments purchased with a
maturity of three months or less to be cash and cash equivalents.
Concentration of Credit Risk
The Company occasionally maintains deposits in excess of federally
insured limits. Statement of Financial Accounting Standards No. 105
identifies these items as a concentration of credit risk requiring
disclosure regardless of the degree of risk. The risk is managed by
maintaining all deposits in high quality financial institutions.
Formulas and Trademarks
Formulas and trademarks are recorded at cost and are amortized over a
period of 15 years using the straight-line method.
Property, Equipment, and Depreciation
Fixed assets are stated at cost. Expenditures for major renewals and
betterments that extend the useful lives of fixed assets are
capitalized. Upon retirement or other disposition, the cost and
related accumulated depreciation are removed from the account and the
resulting gain or loss is reflected in results of operations.
Expenditures for maintenance and repairs are charged to expense as
incurred.
Depreciation is provided primarily by the use of the straight-line
method over the following estimated useful lives of the assets:
Plant Asset Category Estimated Useful Life
---------------------- --------------------
Furniture and fixtures 7 years
Leasehold improvements 31.5 years
Machinery and equipment 5-7 years
Computer software 3 years
<PAGE>14
Revenue Recognition
Revenue will be recognized upon the invoicing and shipping of product.
No revenue has been recognized as of March 31, 2000.
Advertising Costs
Advertising costs are charged to operations and are expensed as
incurred. The total amount charged to expense as of March 31, 2000
was $469,406.
Income Taxes
The Company has adopted Financial Accounting No. 109, "Accounting for
Income Taxes" (FAS 109). Under the provisions of FAS 109, an entity
recognizes deferred tax assets and liabilities for the future tax
consequences of events that have been previously recognized in the
Company's financial statements or tax returns. The measurement of
deferred tax assets and liabilities is based on provisions of the
enacted tax law; the effects of future changes in tax laws or rates
are not anticipated. The adoption of FS 109 did not have an effect
on the Company's financial statements.
Net Income (Loss) Per Share
Primary net income (loss) per share is determined by dividing net
income (loss) by the weighted average number of common shares and
dilutive common shares outstanding during the year.
2. COMMON STOCK
Common stock issued by the Company as payment for services has been
valued by management at fair market value.
3. LEASE COMMITMENTS
The Company leases an automobile under a two-year operating lease
dated February 23, 1998. Lease expense for the year ended March 31,
2000 amounted to $10,854. Lease commitment fees of $10,477 were paid
at inception. This amount was considered a prepaid expense to be
amortized over the life of the lease. On expiration of this lease,
the agreement was renewed for an additional year, expiring February
23, 2001.
4. RELATED PARTY TRANSACTIONS
During the year ended March 31, 2000, the Company rented office space
from a shareholder. Rent expense for the year ended march 31, 2000
was $#7,200. Of this amount, $3,600 was included in accounts payable
at March 31, 2000.
Due from related parties of $27,664 represents amounts paid by the
Company on behalf of its officers and shareholders for personal
expenses.
Due to related parties of $124,830 represents operating expenses paid on
behalf of the Company by companies which are owned and operated by
officers and shareholders of the Company.
5. CONTINGENCIES
The Company is named as a defendant in legal action alleging breach of
fiduciary duties. The Company intends to vigorously defent this action
and is not inclined to seek an out of court settlement. The case is
currently in the discovery stage and the ultimate resolution of the
matter is not ascertainable at this time. Accordingly, no provision
has been made in the financial statements related to this claim.
6. GOING CONCERN STATUS-FUTURE OPERATIONS
The Company began operation in August 8, 1997 and there is no
assurance that it will reach profitability. Since its inception, the
Company has been principally engaged in product and service
development. As shown in the accompanying financial statements, the
Company has incurred net operating losses of $1,744,556 since its
inception The Company is a development stage business. Numerous
problems, many of which are beyond the Company's control, are
frequently experienced by companies in this period of development -
<PAGE>15
marketing and customer support problems, difficulty in dealing with
competition, lack of familiarity on the part of customers and
suppliers, and technical obsolescence.
The Company believes from its initial contacts with potential clients
that there is a substantial market for its services; however, there
can be no assurance that commercial viability can be demonstrated for
said products and services. There can be no assurance that the
Company will ever achieve profitability on a sustained basis, if at
all.
The Company's status as a going concern is dependent on its ability to
successfully implement a marketing plan and generate sufficient
revenues to operate on a profitable basis. The financial statements
do not include any adjustments that might be necessary should the
Company be unable to continue as a going concern.
7. INCOME TAXES
Deferred income taxes reflect the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for
financial reporting purposes an the amounts used for income tax
purposes. The deferred tax asset represent an estimate of the
decrease in taxes payable in future years as a result of temporary
differences existing at the end of the year. The temporary
differences consist principally of net operating loss carryforwards,
(approximately $1,700,000), which are not currently available.
Deferred income taxes consisted of the following at March 31, 2000:
Non-current deferred tax asset $578,000
Valuation allowance (578,000)
---------
Net deferred tax asset $ -0-
=========
The deferred tax asset noted above was calculated utilizing a blended
federal and state income tax rate of 34%.
Net operating loss carryforwards are available for a period of 15
years. The estimated net operating loss of approximately $1,700,000
at march 30, 2000 is scheduled to expire as follows:
2013 $ 150,000
2014 440,000
2015 1,100,000
----------
Total net operating loss $1,700,000
==========
8. RECLASSIFICATION
Certain amounts from inception to March 31, 2000 have been
reclassified to agree with the year ended March 31, 2000 presentation.
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
There have not been any changes in or disagreements with accountants
on accounting and financial disclosure.
<PAGE>16
PART III
ITEM 9. DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY
Board of Directors. The following persons listed below have been
retained to provide services as director until the qualification and
election of his successor. All holders of Common Stock will have the
right to vote for Directors of Micro. The Board of Directors has
primary responsibility for adopting and reviewing implementation of
the business plan of Micro, supervising the development business plan,
review of the officers' performance of specific business functions.
The Board is responsible for monitoring management, and from time to
time, to revise the strategic and operational plans of the
Corporation. Directors receive no cash compensation or fees for
their services rendered in such capacity.
Mr Thistle dedicates 90% of his time to Micro. Ms. Zawadowicz
dedicates 50% of her time to Micro. Mr. Shvetz dedicates 10% of his
time to Micro.
The Executive Officers and Directors are:
Name Position Term(s) of Office
Robert Thistle, age 59 President, Director Inception to Present
Mark Shvetz, age 50 Treasurer, Director Inception to Present
Irene R. Zawadowicz, age 44 Secretary August 28, 1999 to
present
Resumes:
Robert Thistle. Mr. Thistle has been Chief Executive Officer,
President and a Director of Micro from inception. From 1984 to 1991,
Mr. Thistle was President of TR Productions, a Philadelphia production
company. From 1991 to present, Mr. Thistle has worked as a
international business and political consultant working with the
countries of Russia, Pakistan, the Philippines and China. He also
advises Chinese political officials in The People's Republic of China
and is involved in the annual MFN renewal between China and the United
States.
Mark Shvetz. Mr. Shvetz has been the Treasurer and a Director of the
Corporation since inception. Mr. Shvetz has been involved in sales and
marketing for 29 years. From 1993 until he joined Micro, Mr. Shvetz
was self employed selling hospital products and other medical related
equipment. From 1979 through 1993, he was a manager of Timmed Labeling
Systems, Inc., a distributor of hospital products and capital
equipment for a national medical products manufacturer. His
responsibilities included interacting with hospital management and
purchasing decision making staff. Mr. Shvetz received a BS in
Accounting from the University of Connecticut in 1967.
Irene Zawadowicz. Ms. Zawadowicz has been secretary of the
Corporation since August 1999. From 1994 to 1998, Ms. Zawaowicz was
secretary in the human resources department of Butler Hospital. From
1998 to present, Ms. Zawadowicz has been attending Johnson and Wales
University pursing a degree in information science. Ms. Zawadowicz
received an Associate of Arts degree from the Community College of
Rhode Island along with an Office Automation Certificate.
Remuneration. Since inception, the following cash compensation has
been paid by the Corporation to its executive officers, during which
there were three (3) officers.
EXECUTIVE COMPENSATION
<TABLE>
Long-term
Name and Annual Compensation Compensation
Principal Position Year Salary(1) Bonus Awards Other
<S> <C> <C> <C> <C> <C>
Robert Thistle 1999 (3) - - -
President 1998 $12,000
Mark Shvetz 1999 - - - -
1998 (1)
Irene Zawadowicz 1999 (2)
Secretary
</TABLE>
(1)Mr. Shvetz received 100,000 Common Shares for services rendered
from inception.
<PAGE>17
(2)Pursuant to an agreement dated August 28, 1999, Ms. Zawadowicz
received 10,000 common shares as compensation for services. Ms.
Zawadowicz received an additional 10,000 for further services
rendered.
(3) Certain personal expenses of Mr. Thistle were paid for by the
Company. See Related Party Transactions for amounts paid for and by
Mr. Thistle by the Company.
Micro has not entered into Employment Agreements with its
officers.
Board of Directors Compensation. Currently board members receive no
special compensation for meetings or time incurred. Director
liability insurance may be provided to all members of the Board of
Directors. No differentiation shall be made for any further
compensation of "outside directors" and those officers of the
Corporation serving in that capacity.
Stock Option Plan. Micro shall implement an employee stock option
program. The specifics of the plan have yet to be determined.
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT
The following tabulates holdings of shares of the Company by each
person who, subject to the above, at the date of this filing, holders
of record or is known by Management to own beneficially more than
5.0% of the Common Shares and, in addition, by all directors and
officers of the Company individually and as a group. Each named
beneficial owner has sole voting and investment power with respect to
the shares set forth opposite his name.
Current Shareholdings
<TABLE>
<CAPTION>
Percentage of
Number & Class(1) Outstanding
Name and Address of Shares Common Shares
<S> <C> <C>
Robert Thistle
29 Lakeside Drive
Johnston RI 02919 1,500,000 12.06%
Irene R. Zawadowicz
7 Lakeside Drive
Johnston, RI 02919 20,000 .16%
Mark Shvetz
333 Neipsic Road
Glastonbury, CT 02924 0 0%
Phoenix Investment Group, Inc.
5 Cole Drive
Armonk, N& 10504-3004 869,000 6.99%
Anthony Pate
C/o Charles Schwab & Co. Inc.
55 Dorrance Street
Providence, RI 02903 1,200,000 9.65%
Cede & Co C/O Depository Trust Co.
P.O. Box 20
Bowling Green Station
New York NY 10004 5,507,113 44.28%
All Directors & Officers
as a group (3 persons) 1,700,000 13.67%
</TABLE>
(1)Pursuant to Rule 13d-3 under the Securities Exchange Act of 1934,
as amended, beneficial ownership of a security consists of sole or
shared voting power (including the power to vote or direct the voting)
and/or sole or shared investment power (including the power to dispose
<PAGE>18
or direct the disposition) with respect to a security whether through
a contract, arrangement, understanding, relationship or otherwise.
Unless otherwise indicated, each person indicated above has sole power
to vote, or dispose or direct the disposition of all shares
beneficially owned, subject to applicable unity property laws.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
During the year ended March 31, 2000, the Company rented office space
from Robert Thistle, an officer and director of the Company. Rent
expense for the year ended March 31, 2000 was $7,200. Of this amount
$3,600 was included in accounts payable at March 31, 2000.
The Company paid $27,664 on behalf of Robert Thistle and other
shareholders for personal expenses.
Beneficial Health, Inc., a company owned and operated by Robert
Thistle, paid $124,830 in operating expenses on behalf of the Company.
ITEM 13. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON
FORM 8-K
(A) FINANCIAL STATEMENTS AND SCHEDULES
The following financial statements and schedules are filed as part of
this report:
Report of Independent Public Auditors
Balance Sheet.................................
Statement of Operations.......................
Statement of Stockholder's Equity................
Statement of Cash Flows..........................
Notes to Financial Statements..................
Schedules Omitted: All schedules other than those shown have been
omitted because they are not applicable, not required, or the required
information is shown in the financial statements or notes thereto.
<PAGE>19
(b) List of Exhibits
The following exhibits are filed with this report:
(2.1) Articles of Incorporation incorporated by reference to Form 10SB
(2.2) Bylaws incorporated by reference to Form 10SB
(3.1) Common Stock Certificate incorporated by reference to Form 10SB
(B) REPORTS ON FORM 8-K
None
<PAGE>20
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended, the Company has duly caused this
Report to be signed on its behalf by the undersigned duly authorized
person.
Date: July 19, 2000 Micro Laboratories, Inc.
/s/ Robert Thistle
------------------------------------
By: Robert Thistle, President
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, this report has been signed below by the following persons
on behalf of the Company and in the capacities and on the dates
indicated.
/s/Robert Thistle 7/19/2000
------------------------
Robert Thistle
President and Director
(Principal Executive Officer)
/s/Mark Shvetz 7/19/2000
------------------------
Mark Shvetz
Principal Financial Officer/Controller/Director
